December 1, 2015—The Health Resources and Services Administration is repeating its recommendation that healthcare providers follow a specific protocol for disclosing to the government and drug manufacturers that they have violated 340B program requirements.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)